

Table of Contents

Contents	page no.
Chapter 1	1
Review of Literature on Leishmaniasis: Introduction, Current Scenario and Future Prospect	1
Abstract	1
1.1 Introduction	2
1.2 Leishmania: the discovery	3
1.3 Life-cycle of Leishmania	6
1.3.1 Promastigote stage	6
1.3.2 Amastigote stage	7
1.4 Types of Leishmaniasis	7
1.5 Distribution of leishmaniasis (worldwide & India)	10
1.6 Risk factors associated with Leishmaniasis	13
1.7 Current therapeutic approach and their drawbacks	15
1.8 The current problem associated with Treatment failure	17
1.9 Outline of promastigote and amastigote metabolism	21
1.10 Tricarboxylic acid cycle (TCA cycle): An antileishmanial drug target	23
1.11 Citrate synthase	25
1.11.1 Structure of citrate synthase	26
1.11.2 Stereochemistry and Mechanism of enzyme	28
1.11.3 Function of Citrate synthase	29
1.11.3.1 In cellular metabolism	28
1.11.3.2 In inflammation as inflammatory signal	32
1.11.3.3 Acetylation of Histones and Non-histone proteins	35
1.12 Drug Repurposing: An Emerging approach in Drug Discovery	36
1.13 Scope of current approach and objective	37
Chapter 2	40
Modelling of <i>Leishmania donovani</i> citrate synthase and virtual screening of compounds using different databases	40
Abstract	40
2.1 Introduction	41
2.2 Materials & Methods	42

2.2.1 Modelling of Citrate synthase and its validation	42
2.2.2 Ligand Preparation	43
2.2.3 Active site prediction	43
2.2.4 Molecular docking and its analysis	43
2.2.5 ADME analysis	44
2.2.6 Molecular dynamic simulation and its analysis	44
2.3 Results	45
2.3.1 Modelled Structure Prediction and its validation	45
3.3.2 Active site Prediction	46
2.3.3 <i>In silico</i> studies with Natural compound database	49
2.3.3.1 Molecular docking and its analysis	49
2.3.3.2 Pharmacokinetics analysis	51
2.3.3.3 Molecular dynamic simulation and its analysis	54
2.3.4 In silico studies with FDA-approved compound database	60
2.3.4.1 Molecular docking for prediction of efficient inhibitor against Ld citrate synthase	60
2.3.4.2 ADME analysis	63
3.3.3.3 Molecular Dynamic Simulation analysis	67
2.4 Discussion	72
2.5 Conclusion	75
Chapter 3	76
Validation of <i>Leishmania donovani</i> citrate synthase as drug target through biophysical studies	76
Abstract	76
3.1 Introduction	77
3.2 Materials & Methods	78
3.2.1 Materials	78
3.2.2 Molecular Cloning, Expression and Purification of LdCS	79
3.2.3 CD Measurements	80
3.2.4 Intrinsic and Extrinsic Fluorescence studies of LdCS protein at different pH	80
3.2.5 Evaluation of tryptophan position in LdCS protein using Potassium iodide and Acrylamide.	81
3.2.6 Unfolding studies of LdCS protein using Urea and Guanidine Chloride.	81
3.3 Results	82
3.3.1 Cloning, expression, and purification of <i>Leishmania donovani</i> Citrate synthase	82

3.3.2 Determination of the secondary structure of LdCS and its thermal stability	83
3.3.3 Intrinsic and extrinsic fluorescence analysis of LdCS at different pH	84
3.3.4 Assessment of tryptophan location in LdCS protein using Potassium Iodide and Acrylamide.	86
3.3.5 Urea and Guanidine Chloride-induced unfolding studies of LdCS protein	87
3.4 Discussion	89
3.5 Conclusion	91
Chapter 4	93
Evaluation of selected compound as potential inhibitor of citrate synthase: an alternative chemotherapeutic option against leishmaniasis.	93
Abstract	93
4.1 Introduction	94
4.2 Materials & Methods	95
4.2.1 Materials	95
4.2.2 <i>L. donovani</i> and J774 A.1 cell culture maintenance	95
4.2.3 Intrinsic fluorescence measurement of selected compounds.	96
4.2.4 Enzymatic assay and kinetics studies of LdCS	96
4.2.5 Inhibition studies of LdCS	97
4.2.6 Promastigote viability assay	97
4.2.7 Intra-macrophagic amastigotes viability assay	98
4.2.8 Cell toxicity assay in J774A.1 macrophage	98
4.2.9 Statistical analysis	99
4.3 Results	99
4.3.1 Analysis of the interaction of the selected compound with <i>L. donovani</i> citrate synthase by fluorescence spectroscopy	99
4.3.2 Kinetic characterization of <i>L. donovani</i> citrate synthase activity	101
4.3.3 Analysis of inhibition kinetics of <i>L. donovani</i> citrate synthase	102
4.3.4 Effect of the selected compound on promastigote viability	104
4.3.5 Effect of selected compounds on intra-macrophagic amastigote viability	107
4.3.6 Cytotoxic effect of the selected compound on J774A.1 cell lines.	108
4.4 Discussion	111
4.5 Conclusion	112
Chapter 5	114
Deciphering molecular mechanism of anticancer compound abemaciclib on underlying antileishmanial activities.	114

Abstract	114
5.1 Introduction	115
5.2 Materials & Methods	116
5.2.1 Materials	116
5.2.2 <i>L. donovani</i> and J774 A.1 cell culture maintenance	116
5.2.3 Morphological analysis of promastigote	117
5.2.4 Analysis of mitochondrial integrity of promastigote	117
5.2.5 Analysis of ROS generation in promastigote	117
5.2.6 Analysis of mitochondrial membrane potential in promastigote	118
5.2.7 Detection of chromatin condensation in promastigote	118
5.2.8 DNA Laddering assay in promastigote	119
5.2.9 Cell cycle analysis in promastigote	119
5.2.10 Determination of phosphatidylserine exposure and membrane integrity in promastigote	120
5.2.11 Statistical analysis	120
5.3 Results	120
5.3.1 Morphological analysis of Abemaciclib treated promastigote	120
5.3.2 Analysis of effect of Abemaciclib on mitochondrial integrity of promastigote	120
5.3.3 Abemaciclib induced ROS production in Promastigote	122
5.3.4 Abemaciclib induced depolarization of mitochondrial membrane potential in promastigote	123
5.3.5 Analysis of effect of Abemaciclib on nuclear structure of promastigote	124
5.3.6 Abemaciclib induced cell cycle changes in promastigote	125
5.3.7 Abemaciclib induced Genomic DNA fragmentation	126
5.3.8 Abemaciclib induced externalization of phosphatidylserine in the plasma membrane of promastigote	126
5.4 Discussion	127
5.5 Conclusion	129
Chapter 6	130
Summary and Future aspects	130
References	137
APPENDIX A	152
LIST OF PUBLICATION & PATENT	152
APPENDIX B	153
CONFERENCES & WORKSHOPS	153